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Background
Cilostazol and isosorbide mononitrate (ISMN) have properties that may be of benefit in
the context of cerebral small vessel disease and lacunar ischaemic stroke. As both drugs
may influence platelet and haemoglobin levels, we sought to assess their effects using
data from the lacunar intervention trial-1 (LACI-1).
Methods
LACI-1 recruited 57 patients with lacunar ischaemic stroke and randomised them to
ISMN or cilostazol in isolation, or combined for 9 weeks. One group received both drugs
but with a delayed start. Full blood counts were taken at baseline, and weeks 3 and 8.
Platelet function was assessed with remote measurement of surface expression of P-
selectin (CD62P) using kits sensitive to aspirin or clopidogrel at the same timepoints.
Differences in haemoglobin and platelet levels and platelet function were assessed by
multiple linear regression with adjustment for baseline value.
Results
Haemoglobin levels did not differ between the treatment groups at week 8 (Table), whilst
platelet levels were slightly higher in those who received cilostazol compared with no
cilostazol. No differences were noted in platelet function in unstimulated, aspirin or
clopidogrel testing between groups.
Conclusions
Cilostazol and isosorbide mononitrate have no clinically concerning effects on
haemoglobin and platelet levels and function in the short to medium term. Further
assessment of the safety and efficacy of these medications following lacunar ischaemic
stroke is warranted.
Week 8 Cilostazol v none ISMN v none Cil+ISMN v one or other
Full blood count, adjusted
for baseline
MD
(95% CI) p-value
MD
(95% CI) p-value
MD
(95% CI) p-value
Hb, mean (SD) -3.72(-8.39, 0.95) 0.12
-1.03
(-6.92, 4.87) 0.73
-2.35
(-6.82, 2.11) 0.30
Platelets, mean (SD) 35.73(2.81, 68.66) 0.033
3.92
(-32.35, 40.19) 0.83
-7.43
(-36.76, 21.89) 0.62
Platelet function, adjusted
for baseline
Unstimulated median
fluorescence, mean (SD)
-2.90
(-15.09, 9.30) 0.64
-8.23
(-20.68, 4.22) 0.20
7.51
(-4.01, 19.02) 0.20
AA median fluorescence, mean
(SD)
-83.57
(-256.5, 89.37) 0.34
-14.13
(-192.5, 164.24) 0.88
109.73
(-54.01, 273.48) 0.19
ADP median fluorescence,
mean (SD)
-1.33
(-77.64, 74.98) 0.97
-0.50
(-80.14, 79.13) 0.99
11.92
(-60.23, 84.07) 0.75
AA: arachidonic acid (aspirin test); ADP: adenosine diphosphate (clopidogrel test); CI:
confidence intervals; Hb: haemoglobin; ISMN: isosorbide mononitrate; MD: mean
difference; SD: standard deviation
